Mobility paves Samsung’s silver path
The Korean giant’s early bet on mobile phones helped it hit the $10-bn mark in India, but in its 25th year it ...
Dr. Reddy’s Laboratories Ltd has announced the launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL) Single-dose Vial, the therapeutic generic equivalent of Nitropress Injection approved by the US Food and Drug Administration (USFDA).
The Nitropress brand and generics had US sales of approximately $8 million MAT for the most recent twelve months ending in October 2019 according to IQVIA Health, the company informed.
Dr. Reddy’s Sodium Nitroprusside Injection is available in single-dose 50 mg/2 mL (25 mg/mL) vials. Nitropress is a trademark of Hospira, Inc.
Sodium Nitroprusside Injection is not suitable for direct injection. The solution must be further diluted in sterile 5 per cent dextrose injection before infusion. It can cause precipitous decreases in blood pressure. In patients not properly monitored, these decreases can lead to irreversible ischemic injuries or death. Sodium nitroprusside should be used only when available equipment and personnel allow blood pressure to be continuously monitored.
Although acid-base balance and venous oxygen concentration should be monitored and may indicate cyanide toxicity, these laboratory tests provide imperfect guidance.
Please Email the Editor